Molecular dynamics simulation results of Bamocaftor (Blue), Ivacaftor (Red) and Galicaftor (Green) with CFTR (Black). за авторством Naisarg Patel (21772572)

Предмети:

Results of the MMPBSA analysis. за авторством Naisarg Patel (21772572)

Предмети:

Results of Post-Simulation protonation analysis. за авторством Naisarg Patel (21772572)

Предмети:

Table 1_Practitioners’ and researchers’ perspectives on treatment needs and service provision for online child sexual abuse.docx за авторством Felipa Schmidt (17273704)

Data Sheet 2_Decades of failure to prevent harm to patients—where are we going wrong? A mixed methods study of the perspectives of health services staff across Australia and intern... за авторством Mia Bierbaum (5899037)

Data Sheet 3_Decades of failure to prevent harm to patients—where are we going wrong? A mixed methods study of the perspectives of health services staff across Australia and intern... за авторством Mia Bierbaum (5899037)

Data Sheet 1_Decades of failure to prevent harm to patients—where are we going wrong? A mixed methods study of the perspectives of health services staff across Australia and intern... за авторством Mia Bierbaum (5899037)

Participant characteristics. за авторством Zamzam I. A. Ali (21688437)

Предмети: “...acknowledging potential harms...”

Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings. за авторством Diana M. Hendrickx (1507435)

Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. за авторством Diana M. Hendrickx (1507435)

Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. за авторством Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. за авторством Diana M. Hendrickx (1507435)

Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. за авторством Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. за авторством Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. за авторством Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. за авторством Diana M. Hendrickx (1507435)

Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings when using the persistent CMA group as a reference. за авторством Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. за авторством Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... за авторством Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. за авторством Diana M. Hendrickx (1507435)